Petrone Albino, Mormile Flaminio, Bruni Giacomo, Quartieri Michela, Bonsignore Maria R, Marrone Oreste
Department of Respiratory Pathophysiology, "Mariano Santo" Hospital, Cosenza, Italy.
Department of Pneumology, Fondazione Policlinico Universitario Agostino Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
Sleep Med. 2016 Jul;23:21-25. doi: 10.1016/j.sleep.2016.07.002. Epub 2016 Jul 25.
In obstructive sleep apnea (OSA), while both hypothyroidism and hyperthyroidism have been studied, the occurrence of non-thyroidal illness syndrome (NTIS) (normal thyroid stimulating hormone [TSH] with low triiodotironine) has not been investigated. We explored the occurrence of NTIS in patients with moderate to severe OSA and its relationship to the severity of nocturnal respiratory disorders. We also studied the occurrence of subclinical hypothyroidism (SH, ie, high TSH with normal thyroxine) in OSA and changes in circulating TSH, free triiodotironine (fT3) and free thyroxine (fT4) after CPAP treatment.
After a nocturnal respiratory polysomnography, 125 consecutive patients with moderate to severe OSA and 60 control subjects with normal nocturnal respiration were recruited. Morning circulating TSH, fT3, and fT4 were measured in all subjects. In a subsample of patients, nocturnal polysomnography and hormonal determinations were repeated after CPAP treatment for five months.
NTIS was found in 13 (10.4%), and SH in ten (8%) OSA subjects, but not in any control subjects. Patients with NTIS showed worse mean nocturnal oxygen saturation and time with saturation <90% (both p < 0.001). After treatment, NTIS subjects (n = 13) showed an increase in fT3 (p < 0.001) to the normal range, and SH subjects (n = 6) a slight decrease in TSH (p = 0.01). In the patients with normal hormones before treatment (n = 45), no change was observed.
NTIS may occur in OSA patients with severe nocturnal hypoxemia. OSA treatment is followed by an improvement in TSH in patients with abnormal baseline levels of this hormone, and by recovery of NTIS.
在阻塞性睡眠呼吸暂停(OSA)中,虽然甲状腺功能减退和甲状腺功能亢进均已得到研究,但非甲状腺疾病综合征(NTIS)(促甲状腺激素[TSH]正常而三碘甲腺原氨酸降低)的发生情况尚未得到调查。我们探讨了中重度OSA患者中NTIS的发生情况及其与夜间呼吸障碍严重程度的关系。我们还研究了OSA中亚临床甲状腺功能减退(SH,即促甲状腺激素升高而甲状腺素正常)的发生情况以及持续气道正压通气(CPAP)治疗后循环中TSH、游离三碘甲腺原氨酸(fT3)和游离甲状腺素(fT4)的变化。
在进行夜间呼吸多导睡眠监测后,招募了125例连续的中重度OSA患者和60例夜间呼吸正常的对照者。测量了所有受试者早晨的循环TSH、fT3和fT4。在患者的一个亚组中,在CPAP治疗五个月后重复进行夜间多导睡眠监测和激素测定。
在13例(10.4%)OSA受试者中发现了NTIS,10例(8%)中发现了SH,但在任何对照者中均未发现。NTIS患者的平均夜间血氧饱和度和血氧饱和度<90%的时间更差(均p<0.001)。治疗后,NTIS受试者(n=13)的fT3升高(p<0.001)至正常范围,SH受试者(n=6)的TSH略有下降(p=0.01)。在治疗前激素正常的患者(n=45)中,未观察到变化。
NTIS可能发生在夜间严重低氧血症的OSA患者中。OSA治疗后,该激素基线水平异常的患者TSH改善,NTIS恢复。